FindTrial
Sign In

Glucose Variability With DPP-4 Inhibition

Glucose Variability With DPP-4 Inhibition

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01751321
Enrollment
50
Registered
2012-12-17
Start date
2013-05-31
Completion date
2013-10-31
Last updated
2012-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Glucose Variability With DPP-4 Inhibition

Detailed description

Patients with Type 2 Diabetes, age 35-75y., will be included in this double blind randomized placebo controlled study. The sample size of 50 patients completing the 30 day study period is based on statistical input from Merck Research Laboratories, Rahway NJ.

Interventions

DRUGSitagliptin, placebo

sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day

Sponsors

Research Clinical Centre of the Russian Railways, JSC
Lead SponsorOTHER

Study design

Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes * receiving a stable dose of metformin ≥ 1500 mg * HbA1c 7,5% -10/0 %

Exclusion criteria

* Type 1 diabetes * HbA1c \< 7,5% and \> 10,0%

Design outcomes

Primary

MeasureTime frame
glucose variability1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026